Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EEF2K | O00418 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4668166 | 0.89 | SCN1A (0.47) | ALDH1A1 | |
| SCHEMBL6006279 | 0.86 | PTGS2 (0.46) | GAAPTGS2ALDH1A1HSD11B1BCHE | |
| SCHEMBL6671415 | 0.83 | SCN1A (0.42) | ALDH1A1 | |
| SCHEMBL10552641 | 0.81 | SCN1A (0.45) | ALDH1A1 | |
| SCHEMBL4669222 | 0.80 | CYP2D6 (0.53) | ALDH1A1MEN1CYP3A4CYP2C9KMT2A | |
| SCHEMBL4667595 | 0.79 | FFAR1 (0.52) | FFAR1ALDH1A1MEN1CYP3A4CYP2C9 | |
| SCHEMBL10577237 | 0.79 | UTS2R (0.41) | GAAALDH1A1BCHEACHEMEN1 | |
| SCHEMBL22946108 | 0.77 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL15000821 | 0.75 | ALDH1A1 (0.54) | GAAPTGS2FFAR1ALDH1A1BCHE | |
| SCHEMBL14380256 | 0.75 | ALDH1A1 (0.40) | ALDH1A1HSD11B1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1930308-A1 | Pharmaceutical agents for the treatment of cerebral amyloidosis | NYMOX CORPORATION (CA) | 2008-06-11 | — | — | EP | disclosed |
| EP-0983222-B1 | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS | NYMOX CORP (CA) | 2007-11-28 | — | — | EP | disclosed |
| EP-0983222-A1 | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS | NYMOX CORPORATION (CA) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998052898-A9 | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS | NYMOX CORP (CA) | 1999-04-01 | — | — | WO | disclosed |
| WO-1998052898-A1 | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS | NYMOX CORPORATION (CA) | 1998-11-26 | — | — | WO | disclosed |